QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19

Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.

[Article in English, Portuguese]

Authors

Tan Chen Wu¹, Luciana Sacilotto¹, Francisco Carlos da Costa Darrieux¹, Cristiano Faria Pisani¹, Sissy Lara de Melo¹, Denise Tessariol Hachul¹, Mauricio Scanavacca¹

Affiliation

¹ Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.

No abstract available

MeSH terms

Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Antimalarials / adverse effects
Antimalarials / therapeutic use*
Azithromycin / adverse effects
Azithromycin / therapeutic use*
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Electrocardiography
Humans
Hydroxychloroquine / adverse effects
Hydroxychloroquine / therapeutic use*
Long QT Syndrome*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
SARS-CoV-2
Torsades de Pointes / prevention & control*
Treatment Outcome

Substances

Anti-Bacterial Agents
Antimalarials
Hydroxychloroquine
Azithromycin